These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores. Miserez AR; Martin FJ; Spirk D Atherosclerosis; 2018 Oct; 277():282-288. PubMed ID: 30270060 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland. Mickiewicz A; Chmara M; Futema M; Fijalkowski M; Chlebus K; Galaska R; Bandurski T; Pajkowski M; Zuk M; Wasag B; Limon J; Rynkiewicz A; Gruchala M Atherosclerosis; 2016 Jun; 249():52-8. PubMed ID: 27062410 [TBL] [Abstract][Full Text] [Related]
27. Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia. Rieck L; Bardey F; Grenkowitz T; Bertram L; Helmuth J; Mischung C; Spranger J; Steinhagen-Thiessen E; Bobbert T; Kassner U; Demuth I Clin Genet; 2020 Nov; 98(5):457-467. PubMed ID: 32770674 [TBL] [Abstract][Full Text] [Related]
28. Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary Angiography. Li JJ; Li S; Zhu CG; Wu NQ; Zhang Y; Guo YL; Gao Y; Li XL; Qing P; Cui CJ; Xu RX; Jiang ZW; Sun J; Liu G; Dong Q Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):570-579. PubMed ID: 27932355 [TBL] [Abstract][Full Text] [Related]
29. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. Humphries SE; Cranston T; Allen M; Middleton-Price H; Fernandez MC; Senior V; Hawe E; Iversen A; Wray R; Crook MA; Wierzbicki AS J Mol Med (Berl); 2006 Mar; 84(3):203-14. PubMed ID: 16389549 [TBL] [Abstract][Full Text] [Related]
30. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene. Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007 [TBL] [Abstract][Full Text] [Related]
31. Spectrum of mutations of familial hypercholesterolemia in the 22 Arab countries. Alhababi D; Zayed H Atherosclerosis; 2018 Dec; 279():62-72. PubMed ID: 30415195 [TBL] [Abstract][Full Text] [Related]
33. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients. Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841 [TBL] [Abstract][Full Text] [Related]
34. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Futema M; Ramaswami U; Tichy L; Bogsrud MP; Holven KB; Roeters van Lennep J; Wiegman A; Descamps OS; De Leener A; Fastre E; Vrablik M; Freiberger T; Esterbauer H; Dieplinger H; Greber-Platzer S; Medeiros AM; Bourbon M; Mollaki V; Drogari E; Humphries SE Atherosclerosis; 2021 Feb; 319():108-117. PubMed ID: 33508743 [TBL] [Abstract][Full Text] [Related]
35. Genetic basis of index patients with familial hypercholesterolemia in Chinese population: mutation spectrum and genotype-phenotype correlation. Sun D; Zhou BY; Li S; Sun NL; Hua Q; Wu SL; Cao YS; Guo YL; Wu NQ; Zhu CG; Gao Y; Cui CJ; Liu G; Li JJ Lipids Health Dis; 2018 Nov; 17(1):252. PubMed ID: 30400955 [TBL] [Abstract][Full Text] [Related]
36. Relationship of Familial Hypercholesterolemia and High Low-Density Lipoprotein Cholesterol to Ischemic Stroke: Copenhagen General Population Study. Beheshti S; Madsen CM; Varbo A; Benn M; Nordestgaard BG Circulation; 2018 Aug; 138(6):578-589. PubMed ID: 29593013 [TBL] [Abstract][Full Text] [Related]
37. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942 [TBL] [Abstract][Full Text] [Related]
38. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia. Santos PC; Morgan AC; Jannes CE; Turolla L; Krieger JE; Santos RD; Pereira AC Atherosclerosis; 2014 Mar; 233(1):206-10. PubMed ID: 24529145 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of clinical diagnosis criteria of familial ligand defective apoB 100 and lipoprotein phenotype comparison between LDL receptor gene mutations affecting ligand-binding domain and the R3500Q mutation of the apoB gene in patients from a South European population. Ejarque I; Real JT; Martinez-Hervas S; Chaves FJ; Blesa S; Garcia-Garcia AB; Millan E; Ascaso JF; Carmena R Transl Res; 2008 Mar; 151(3):162-7. PubMed ID: 18279815 [TBL] [Abstract][Full Text] [Related]
40. Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. Raal FJ; Bahassi EM; Stevens B; Turner TA; Stein EA Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2747-2755. PubMed ID: 32878475 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]